Cargando…

Introducing high-flow nasal cannula oxygen therapy at the intermediate care unit: expanding the range of supportive pulmonary care

BACKGROUND: Non-invasive respiratory support is a frequent indication for intermediate care unit (IMCU) admission. Extending the possibilities of respiratory support at the IMCU with high-flow nasal cannula oxygen therapy (HFNC) may prevent intensive care unit (ICU) transfer and invasive ventilation...

Descripción completa

Detalles Bibliográficos
Autores principales: Plate, Joost D J, Leenen, Luke P H, Platenkamp, Marc, Meijer, Joost, Hietbrink, Falco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078271/
https://www.ncbi.nlm.nih.gov/pubmed/30109275
http://dx.doi.org/10.1136/tsaco-2018-000179
_version_ 1783345061883281408
author Plate, Joost D J
Leenen, Luke P H
Platenkamp, Marc
Meijer, Joost
Hietbrink, Falco
author_facet Plate, Joost D J
Leenen, Luke P H
Platenkamp, Marc
Meijer, Joost
Hietbrink, Falco
author_sort Plate, Joost D J
collection PubMed
description BACKGROUND: Non-invasive respiratory support is a frequent indication for intermediate care unit (IMCU) admission. Extending the possibilities of respiratory support at the IMCU with high-flow nasal cannula oxygen therapy (HFNC) may prevent intensive care unit (ICU) transfer and invasive ventilation. However, the safety and limitations of HFNC administration in the stand-alone IMCU setting are not yet studied. This study therefore aims to investigate to what extent and in which patients HFNC can safely be administered at a stand-alone mixed surgical IMCU. METHODS: A case series, using retrospectively collected data, was performed after the first year of introducing HFNC at a stand-alone IMCU. The following variables were collected: indication to start HFNC, vital parameters and arterial blood gas measurements. Primary outcome was 30-day mortality. Secondary outcome was transfer to the ICU. RESULTS: A total of 96 admissions were included. The indications to start HFNC at the IMCU were predominantly pathologies of pulmonary origin (n=67, 69.8%). Less frequent indications were prolonged support postweaning (n=15), non-pulmonary sepsis (n=7) and post-trauma resuscitation (n=6). The average PaO(2)/FiO(2)ratio at start of HFNC was 152 (95% CI 139 to 165). 30-day mortality was 7, of which 5 were admitted with treatment restrictions (no ICU policy) and 2 deaths were unrelated to HFNC. Transfer to the ICU occurred in 18 (18.8%) admissions, of which 12 received invasive mechanical ventilation. Reason for ICU transfer was mainly PaO2/FiO2 ratio<100 under maximum non-invasive treatment (n=12, 66.7%). Application of HFNC at the IMCU prevented 162 days of ICU admission. DISCUSSION: Administration of HFNC at a stand-alone surgical IMCU may be safe as it expands the range of supportive possibilities and thereby reduces the need for ICU admissions. Pulmonary indications to start HFNC increase the risk of ICU transfer and mechanical ventilation. LEVEL OF EVIDENCE: Level VI.
format Online
Article
Text
id pubmed-6078271
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-60782712018-08-14 Introducing high-flow nasal cannula oxygen therapy at the intermediate care unit: expanding the range of supportive pulmonary care Plate, Joost D J Leenen, Luke P H Platenkamp, Marc Meijer, Joost Hietbrink, Falco Trauma Surg Acute Care Open Original Article BACKGROUND: Non-invasive respiratory support is a frequent indication for intermediate care unit (IMCU) admission. Extending the possibilities of respiratory support at the IMCU with high-flow nasal cannula oxygen therapy (HFNC) may prevent intensive care unit (ICU) transfer and invasive ventilation. However, the safety and limitations of HFNC administration in the stand-alone IMCU setting are not yet studied. This study therefore aims to investigate to what extent and in which patients HFNC can safely be administered at a stand-alone mixed surgical IMCU. METHODS: A case series, using retrospectively collected data, was performed after the first year of introducing HFNC at a stand-alone IMCU. The following variables were collected: indication to start HFNC, vital parameters and arterial blood gas measurements. Primary outcome was 30-day mortality. Secondary outcome was transfer to the ICU. RESULTS: A total of 96 admissions were included. The indications to start HFNC at the IMCU were predominantly pathologies of pulmonary origin (n=67, 69.8%). Less frequent indications were prolonged support postweaning (n=15), non-pulmonary sepsis (n=7) and post-trauma resuscitation (n=6). The average PaO(2)/FiO(2)ratio at start of HFNC was 152 (95% CI 139 to 165). 30-day mortality was 7, of which 5 were admitted with treatment restrictions (no ICU policy) and 2 deaths were unrelated to HFNC. Transfer to the ICU occurred in 18 (18.8%) admissions, of which 12 received invasive mechanical ventilation. Reason for ICU transfer was mainly PaO2/FiO2 ratio<100 under maximum non-invasive treatment (n=12, 66.7%). Application of HFNC at the IMCU prevented 162 days of ICU admission. DISCUSSION: Administration of HFNC at a stand-alone surgical IMCU may be safe as it expands the range of supportive possibilities and thereby reduces the need for ICU admissions. Pulmonary indications to start HFNC increase the risk of ICU transfer and mechanical ventilation. LEVEL OF EVIDENCE: Level VI. BMJ Publishing Group 2018-08-03 /pmc/articles/PMC6078271/ /pubmed/30109275 http://dx.doi.org/10.1136/tsaco-2018-000179 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Article
Plate, Joost D J
Leenen, Luke P H
Platenkamp, Marc
Meijer, Joost
Hietbrink, Falco
Introducing high-flow nasal cannula oxygen therapy at the intermediate care unit: expanding the range of supportive pulmonary care
title Introducing high-flow nasal cannula oxygen therapy at the intermediate care unit: expanding the range of supportive pulmonary care
title_full Introducing high-flow nasal cannula oxygen therapy at the intermediate care unit: expanding the range of supportive pulmonary care
title_fullStr Introducing high-flow nasal cannula oxygen therapy at the intermediate care unit: expanding the range of supportive pulmonary care
title_full_unstemmed Introducing high-flow nasal cannula oxygen therapy at the intermediate care unit: expanding the range of supportive pulmonary care
title_short Introducing high-flow nasal cannula oxygen therapy at the intermediate care unit: expanding the range of supportive pulmonary care
title_sort introducing high-flow nasal cannula oxygen therapy at the intermediate care unit: expanding the range of supportive pulmonary care
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078271/
https://www.ncbi.nlm.nih.gov/pubmed/30109275
http://dx.doi.org/10.1136/tsaco-2018-000179
work_keys_str_mv AT platejoostdj introducinghighflownasalcannulaoxygentherapyattheintermediatecareunitexpandingtherangeofsupportivepulmonarycare
AT leenenlukeph introducinghighflownasalcannulaoxygentherapyattheintermediatecareunitexpandingtherangeofsupportivepulmonarycare
AT platenkampmarc introducinghighflownasalcannulaoxygentherapyattheintermediatecareunitexpandingtherangeofsupportivepulmonarycare
AT meijerjoost introducinghighflownasalcannulaoxygentherapyattheintermediatecareunitexpandingtherangeofsupportivepulmonarycare
AT hietbrinkfalco introducinghighflownasalcannulaoxygentherapyattheintermediatecareunitexpandingtherangeofsupportivepulmonarycare